Sumitomo Chemical's F3/26 Results Beat Expectations; F3/27 Likely to Return to a Growth Trajectory

Overview

This report is Morgan Stanley's commentary on Sumitomo Chemical's F3/26 results. The core conclusion is that core operating profit was better than expected, the F3/27 guidance still shows profit growth even after conservatively incorporating external headwinds, and the information released around the business strategy is also positive.

Core views

Morgan Stanley believes Sumitomo Chemical has returned to a growth trajectory. F3/26 core operating profit beat company guidance and Morgan Stanley's forecast, mainly driven by improvements in pharmaceuticals and petrochemicals, offsetting declines in ICT-related profits. For F3/27, the company guided for core operating profit of ¥215bn, up 3% year on year; the report believes petrochemicals, especially improved refining margins at Petro Rabigh, could provide further upside. Agrochemical products such as Indiflin and biorationals have growth potential, and the ICT business is also adjusting its structure around a semiconductor materials transition driven by AI.

Analysis framework

The report assesses the results by comparing them with guidance, segment profit changes, company strategy commentary, dividend plans, valuation, and peer multiples. Valuation uses an SOTP method and references peer P/E multiples across different business segments as well as Sumitomo Pharma's target price.

Methodology notes

• Valuation methodsSOTP valuation

  Sum-of-the-parts valuation

  Morgan Stanley values the petrochemical major using SOTP to reflect Sumitomo Chemical's broad business scope.

• Valuation methodsPeer P/E multiple

  Peer price-to-earnings multiples

  The report uses average listed peer multiples: Agro & Life Solutions 12.0x, ICT & Mobility Solutions 12.0x, Essential & Green Materials 7.5x.

• ratingMorgan Stanley relative rating system

  Relative rating system

  Overweight indicates an expected risk-adjusted total return over the next 12-18 months above the average level for the analysts' covered industry.

Asset mapping & comparison

Structured mapping from thesis to named assets (strengths, weaknesses, peers, risks).

• Sumitomo Chemical (4005.T)

  Report coverage subject, Japanese chemical stock

  Strengths

  F3/26 core operating profit beat expectations, F3/27 guidance is still growing, the dividend plan has been raised, and valuation is still seen as attractive.

  Weaknesses

  ICT-related profits declined in F3/26, and some businesses are still affected by exchange rates, LCD materials demand, and production/operations issues.

  Comparison

  Among Morgan Stanley's Japanese chemical coverage, it is rated O, alongside Asahi Kasei, Mitsubishi Chemical Group, Mitsui Chemicals, and Tosoh.

  Risks

  Petrochemical supply and demand, yen appreciation, LCD materials demand, production issues, and the Middle East situation may all affect profits.

• Sumitomo Pharma

  An important component of group profit and SOTP valuation

  Strengths

  It made a significant contribution to profit improvement in F3/26, and the report's valuation also incorporates its target price.

  Weaknesses

  The sustainability of pharmaceutical profits still needs to be monitored.

  Comparison

  Compared with the traditional petrochemical business, the pharmaceutical segment makes a more pronounced contribution to the group's profit recovery.

  Risks

  Volatility in the pharmaceutical business, and R&D/commercialization progress falling short of expectations.

• Petro Rabigh

  One source of improved petrochemical profitability and upside

  Strengths

  Improving refining margins could drive upside in F3/27.

  Weaknesses

  Petrochemicals and refining are highly cyclical.

  Comparison

  Compared with other group segments, Petro Rabigh is more sensitive to petrochemical profit elasticity.

  Risks

  Middle East tensions, a decline in refining margins, and operational volatility.

Key data

• F3/26 core operating profit¥208.376bnAbove company guidance of ¥200bn and Morgan Stanley's forecast of ¥203bn.
• F3/27 company core operating profit guidance¥215bnUp 3% year on year, already including about ¥10bn of negative impact from worsening Middle East conditions.
• F3/27 Morgan Stanley net profit forecast¥100bnHigher than company guidance of ¥70bn and consensus of ¥79.486bn.
• F3/27 Morgan Stanley EPS forecast¥61.1Company guidance is ¥42.4, and consensus is ¥48.6.
• F3/27 Morgan Stanley dividend forecast¥24.0/shareThe company plans ¥16.0/share and said it hopes to return to ¥24 earlier.
• Target price¥850Based on F3/28e EPS of ¥80.0, 10.6x P/E, 1.3x P/B, and an SOTP framework.
• Closing price¥604Price as of 2026-05-14.
• Current market cap¥986.8bnFrom the report's rating summary.

Impact & implications

If F3/27 profit growth and segment profit improvements materialize, Sumitomo Chemical may still have further re-rating room even after the post-earnings share-price surge. The key implication is that the market may need to reassess the sustainability of the company's recovery from a trough, the leverage to petrochemical cycle improvement, and the support that the pharmaceuticals and agrochemicals businesses provide to group profits.

Risks

• A sharp decline in LCD materials demand.
• PRC-related operating issues or plant problems.
• A stronger yen; the report assumes ¥150/US$ from F3/27 onward and notes that each ¥1 change in the exchange rate affects operating profit.
• Supply and demand for key petrochemical products, and pricing, fall short of expectations.
• Further deterioration in the Middle East situation creates additional negative pressure on profits.
• Failure to gain market share in electronic materials.

What to watch

• Whether F3/27 core operating profit exceeds company guidance of ¥215bn.
• Whether Petro Rabigh's refining margins and petrochemical profitability improvements continue.
• Whether growth in agrochemical products Indiflin and biorationals is realized.
• Whether the ICT business can adapt to AI-driven changes in semiconductor materials demand.
• The timing of dividend restoration to ¥24 per share.
• Changes in the yen/US dollar exchange rate and LCD materials demand.